PDCD1LG2 Antikörper (PE)

Produktnummer ABIN2663272

Der Maus Monoklonal Anti-PDCD1LG2-Antikörper wurde für FACS und ICFC validiert. Er ist geeignet, PDCD1LG2 in Proben von Human zu detektieren.

Kurzübersicht für PDCD1LG2 Antikörper (PE) (ABIN2663272)

Target: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PDCD1LG2 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Klon: 24F-10C12

Produktdetails anti-PDCD1LG2 Antikörper (PE)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu PDCD1LG2

Target: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Andere Bezeichnung: CD273

Hintergrund: CD273, known as B7-DC, is also called programmed death ligand 2 (PDL2). This ligand is a 25 kD type I transmembrane protein and a member of B7 family within the immunoglobulin receptor superfamily and is expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 has been reported to be stimulatory on dendritic cells when cross-linked and to inhibit T cell activation upon engaging the PD-1 receptor. CD273 has also been reported to bind to an alternative receptor and to mediate T cell activation through such non-PD1 mediated interactions.